Lineage Cell Therapeutics Inc Quick Ratio (LCTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lineage Cell Therapeutics Inc   (NYSE: LCTX)

Lineage Cell Therapeutics Inc 's Quick Ratio

LCTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 5.13 above Lineage Cell Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 67 other companies have achieved higher Quick Ratio than Lineage Cell Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 681, from total ranking in the first quarter 2026 at 977.

Explain Quick Ratio?
How much Cash & cash equivalents LCTX´s has?
What are LCTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LCTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -7.83 % -37.75 % -18.67 % -32.33 % -29.58 %
Y / Y Cash & cash equivalent Change 20.26 % 11.43 % 16.68 % 23.77 % 9.85 %
Quick Ratio MRQ 5.13 6.55 4.91 4.32 3.93
LCTX's Total Ranking # 681 # 977 # 978 # 1070 # 1116
Seq. Current Liabilities Change 21.67 % -28.32 % 21.16 % -12.77 % -17.82 %
Seq. Cash & cash equivalent Change -4.73 % -4.3 % 37.78 % -4.26 % -11.73 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 68
Healthcare Sector # 298
Overall Market # 793


Quick Ratio Statistics
High Average Low
15.02 4.23 0.79
(Dec 31 2010)   (Dec 31 2013)




Financial Statements
Lineage Cell Therapeutics Inc 's Current Liabilities $ 10 Millions Visit LCTX's Balance sheet
Lineage Cell Therapeutics Inc 's Cash & cash equivalent $ 51 Millions Visit LCTX's Balance sheet
Source of LCTX's Sales Visit LCTX's Sales by Geography


Cumulative Lineage Cell Therapeutics Inc 's Quick Ratio

LCTX's Quick Ratio for the trailling 12 Months

LCTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -24.91 % -29.45 % -25.68 % -26.23 % -21.69 %
Y / Y Cash & cash equivalent TTM Growth 17.45 % 14.99 % 14.65 % 18.74 % 7.4 %
Quick Ratio TTM 5.17 4.84 4.18 3.78 3.3
Total Ranking TTM # 386 # 445 # 311 # 369 # 464
Seq. Current Liabilities TTM Growth -2.12 % -11.08 % -5.53 % -8.67 % -8.04 %
Seq. Cash & cash equivalent TTM Growth 4.46 % 2.94 % 4.47 % 4.55 % 2.27 %

Quick ratio ranking by company, industry and sector >> Back to LCTX Financial Strength Comparisons >> Go to Compare LCTX Quick Ratio to its Competitors

On the trailing twelve months basis LCTX Cash & cash equivalent grew by 20.26 % in Q2 2026 year on year, while Current Liabilities grew to $10 millions, this led to increase in in Lineage Cell Therapeutics Inc 's Quick Ratio to 5.17, above LCTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 139 other companies have achieved higher Quick Ratio than Lineage Cell Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2899.

Explain Quick Ratio?
How much Cash & cash equivalents LCTX´s has?
What are LCTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 140
Healthcare Sector # 866
Within the Market # 681


trailing twelve months Quick Ratio Statistics
High Average Low
7.19 2.99 1.14
(Jun 30 2012)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Voyager Therapeutics Inc   13.75 $ 229.369  Millions$ 16.685  Millions
Leonabio Inc   13.07 $ 102.167  Millions$ 7.817  Millions
Lenz Therapeutics Inc   12.82 $ 220.651  Millions$ 17.212  Millions
X4 Pharmaceuticals Inc  11.41 $ 220.874  Millions$ 19.366  Millions
Quince Therapeutics Inc   11.30 $ 116.000  Millions$ 10.262  Millions
Compass Therapeutics Inc   11.15 $ 179.879  Millions$ 16.128  Millions
Odyssey Therapeutics, Inc.  10.98 $ 310.575  Millions$ 28.295  Millions
Protara Therapeutics Inc  10.70 $ 142.494  Millions$ 13.319  Millions
Engene Therapeutics Inc   9.79 $ 266.320  Millions$ 27.209  Millions
Eikon Therapeutics Inc   9.61 $ 531.178  Millions$ 55.296  Millions
Zura Bio Limited  9.46 $ 205.134  Millions$ 21.690  Millions
4d Molecular Therapeutics Inc   9.16 $ 436.624  Millions$ 47.673  Millions
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions
Denali Therapeutics Inc   7.89 $ 710.471  Millions$ 90.083  Millions
Redwoods Acquisition Corp  7.69 $ 9.300  Millions$ 1.210  Millions
Cardiff Oncology Inc   7.04 $ 76.005  Millions$ 10.797  Millions
Black Diamond Therapeutics Inc   6.98 $ 110.506  Millions$ 15.843  Millions
Immunovant Inc   6.81 $ 797.798  Millions$ 117.102  Millions
Scholar Rock Holding Corp  6.81 $ 492.088  Millions$ 72.242  Millions
Fennec Pharmaceuticals Inc   6.66 $ 82.498  Millions$ 12.394  Millions
Krystal Biotech Inc   6.64 $ 845.600  Millions$ 127.397  Millions
Caribou Biosciences Inc   6.33 $ 113.800  Millions$ 17.974  Millions
Cognition Therapeutics inc   6.24 $ 34.012  Millions$ 5.450  Millions
C4 Therapeutics Inc   6.24 $ 300.854  Millions$ 48.247  Millions
Repligen Corp  5.94 $ 810.449  Millions$ 136.403  Millions
Cabaletta Bio Inc   5.64 $ 225.101  Millions$ 39.910  Millions

Date modified: 2026-09-08T18:37:39+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.